Table 2.

OR and 95% CI for risk of prostate cancer across quintiles of plasma coenzyme Q10 (CoQ10)

CoQ10 quintiles, ng/mLCasesControlsaORb (95% CI)Ptrendc
All casesQ1 (≤1,017)641171.00
Q2 (1,017–1,288)611200.93 (0.59–1.47)
Q3 (1,288–1,623)521280.73 (0.44–1.18)
Q4 (1,623–2,106)661151.13 (0.69–1.80)
Q5 (≥2,106)641161.05 (0.63–1.75)0.50
Excluding matched sets in which controls had PSA > 4.0 ng/mLQ1 (≤1,017)43711.00
Q2 (1,017–1,288)43760.88 (0.49–1.58)
Q3 (1,288–1,623)34870.56 (0.30–1.05)
Q4 (1,623–2,106)41820.78 (0.43–1.43)
Q5 (≥2,106)44800.89 (0.47–1.69)0.95
  • aControls were men matched to cases on geographic location (California or Hawaii), ethnicity (African American, Japanese American, Latino, Native Hawaiian, or white), year of birth (±1 year), date (±6 months) and time (±2 hours) of specimen collection, fasting status (0 to <6, 6 to <8, 8 to <10, and 10+ hours).

  • bEstimated by conditional logistic regression with matched sets as strata, with additional adjustment for age at blood draw, fasting hours prior to blood draw and years of education as continuous variables, as well as family history of prostate cancer and BMI.

  • cLinear dose–response in the logit of risk was estimated by a Wald test for CoQ10 modeled as a trend variable assigned the median value of the appropriate category.